IP Library Granted Patent US 9,796,744
Granted Patent B2
US 9,796,744 · App. 12/514,653 · Granted Oct 24, 2017

Patent

Inventors: Johannes Hübner (Freiburg, DE); Otto Holst (Bad Oldesloe, DE); Christian Theilacker (Freiburg, DE); Zbigniew Kaczynski (Gdansk, PL)
Assignee: UNIVERSITÄTSKLINIKUM FREIBURG
C07H15/04A61K39/07C08B37/006G01N33/56944G01N2333/315
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,796,744
App. No.
12/514,653
Granted
Oct 24, 2017
Kind
B2
Abstract

The present invention generally relates to the field of detecting and preventing infectious diseases caused by Enterococcus faecalis and/or Enterococcus faecium . More specifically, the invention relates to an Enterococcus faecalis and/or Enterococcus faecium antigen which comprises at least one unit having the following general formula:

Claims (14)

1. A vaccine comprising an isolated immunogenic Enterococcus faecalis antigen and an immunologically effective amount of an adjuvant, wherein the isolated antigen consists of, or consists essentially of, one or more units of Formula I:

wherein R 1 is OH, X is O, Y is O and CA is lactyl.

2. The vaccine of claim 1 , wherein the isolated antigen consists of two sugars, wherein the two sugars are in the D configuration.

3. The vaccine of claim 1 , wherein the isolated antigen consists of one or more units of the following formula:

wherein R 1 is OH, X is O, Y is O and CA is lactyl.

4. The vaccine of claim 1 , wherein the isolated antigen has a molecular weight of approx, 1000-200000 Da.

5. The vaccine of claim 1 , wherein the isolated antigen consists of at least 5 units of Formula I per molecule.

6. The vaccine of claim 1 , wherein the isolated antigen is bound to a support.

7. The vaccine of claim 1 , wherein the binding to the support is covalent binding.

8. The vaccine of claim 1 wherein the isolated antigen consists of one or more units

of Formula I:

wherein R 1 is OH, X is O, Y is O and CA is lactyl.

9. The vaccine of claim 1 , wherein the isolated antigen consists essentially of one or more units of Formula I:

wherein R 1 is OH, X is O, Y is O and CA is lactyl.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2009
From: HUEBNER, JOHANNES; THEILACKER, CHRISTIAN; HOLST, OTTO; KACZYNSKI, ZBIGNIEW
To: UNIVERSITATSKLINIKUM FREIBURG
Reel/Frame 022922/0395 →
Priority Claims (1)
DE 10 2006 053 385 · Nov 13, 2006 · national
Continuity (1)
Related Publication 20100055112A1 · Mar 4, 2010